PPARG and neoplasm: The selective inhibition of the noncanonical TGF-β pathway involving MEK-ERK signaling, paralleled by the promotion of adipogenesis and inhibition of tumor-associated inflammation via PPARγ agonists may irreversibly differentiate breast cancer cell into adipocytes (6, 100, 159).